A	B	C	D	E	F
1	Main
2		Brand Name	Zaltrap
3		Generic Name	aflibercept
4		Mechanism	VEGF A/B trap.
5		Indication	Colorectal cancer
6		Competition
7		Economics	50/50 with SNY
8		Administration	IV
9		Clinical Trials
10
11			Phase 3 Refractory metastatic colorectal cancer (VELOUR)'
12			ECOG 3200		Velour
13			FOLFOX	AV + Folfox	FOLFIRI	ZAL + FOL
14		n	292	293	612	614
15		ORR	0.086	0.227	0.111	0.198
16		Median PFS (mths)	4.5	7.5	4.7	6.9
17		Median OS (mths)	10.8	12.9	12.1	13.5
18
19			Expect BLA filing by end of year.
20			Not clear why this drug would garner much market share
21
22			Phase 3, 2nd line NSCLC
23			n = 913, in combination with Docetaxel
24			Did not improve OS